CN113345543A - Suggestion generation method and system based on patient information - Google Patents
Suggestion generation method and system based on patient information Download PDFInfo
- Publication number
- CN113345543A CN113345543A CN202110746320.1A CN202110746320A CN113345543A CN 113345543 A CN113345543 A CN 113345543A CN 202110746320 A CN202110746320 A CN 202110746320A CN 113345543 A CN113345543 A CN 113345543A
- Authority
- CN
- China
- Prior art keywords
- patient
- gene
- information
- mutation
- immunotherapy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 39
- 238000003745 diagnosis Methods 0.000 claims abstract description 39
- 108090000623 proteins and genes Proteins 0.000 claims description 256
- 230000035772 mutation Effects 0.000 claims description 142
- 238000009169 immunotherapy Methods 0.000 claims description 99
- 230000001024 immunotherapeutic effect Effects 0.000 claims description 43
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims description 35
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims description 35
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims description 35
- 230000000694 effects Effects 0.000 claims description 33
- 230000002068 genetic effect Effects 0.000 claims description 28
- 102000009512 Cyclin-Dependent Kinase Inhibitor p15 Human genes 0.000 claims description 21
- 108010009356 Cyclin-Dependent Kinase Inhibitor p15 Proteins 0.000 claims description 21
- 230000003321 amplification Effects 0.000 claims description 21
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 21
- 206010059866 Drug resistance Diseases 0.000 claims description 19
- 238000001514 detection method Methods 0.000 claims description 19
- -1 CCKN2A Proteins 0.000 claims description 18
- 108091008794 FGF receptors Proteins 0.000 claims description 18
- 101000628562 Homo sapiens Serine/threonine-protein kinase STK11 Proteins 0.000 claims description 18
- 108090000484 Kelch-Like ECH-Associated Protein 1 Proteins 0.000 claims description 18
- 102000004034 Kelch-Like ECH-Associated Protein 1 Human genes 0.000 claims description 18
- 108010029755 Notch1 Receptor Proteins 0.000 claims description 18
- 102000001759 Notch1 Receptor Human genes 0.000 claims description 18
- 102100026715 Serine/threonine-protein kinase STK11 Human genes 0.000 claims description 18
- 102000052178 fibroblast growth factor receptor activity proteins Human genes 0.000 claims description 18
- 101000997835 Homo sapiens Tyrosine-protein kinase JAK1 Proteins 0.000 claims description 17
- 101000997832 Homo sapiens Tyrosine-protein kinase JAK2 Proteins 0.000 claims description 17
- 102100033438 Tyrosine-protein kinase JAK1 Human genes 0.000 claims description 17
- 102100033444 Tyrosine-protein kinase JAK2 Human genes 0.000 claims description 17
- 230000037430 deletion Effects 0.000 claims description 17
- 238000012217 deletion Methods 0.000 claims description 17
- 102000006311 Cyclin D1 Human genes 0.000 claims description 9
- 108010058546 Cyclin D1 Proteins 0.000 claims description 9
- 102000012199 E3 ubiquitin-protein ligase Mdm2 Human genes 0.000 claims description 9
- 108050002772 E3 ubiquitin-protein ligase Mdm2 Proteins 0.000 claims description 9
- 102100031734 Fibroblast growth factor 19 Human genes 0.000 claims description 9
- 102100028043 Fibroblast growth factor 3 Human genes 0.000 claims description 9
- 102100028072 Fibroblast growth factor 4 Human genes 0.000 claims description 9
- 101000846394 Homo sapiens Fibroblast growth factor 19 Proteins 0.000 claims description 9
- 101001060280 Homo sapiens Fibroblast growth factor 3 Proteins 0.000 claims description 9
- 101001060274 Homo sapiens Fibroblast growth factor 4 Proteins 0.000 claims description 9
- 102000017274 MDM4 Human genes 0.000 claims description 9
- 108050005300 MDM4 Proteins 0.000 claims description 9
- 108010074708 B7-H1 Antigen Proteins 0.000 claims description 7
- 102000008096 B7-H1 Antigen Human genes 0.000 claims description 7
- 230000002939 deleterious effect Effects 0.000 claims description 7
- 230000002137 anti-vascular effect Effects 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 4
- 238000004891 communication Methods 0.000 claims description 3
- 208000013010 hypopharyngeal carcinoma Diseases 0.000 claims description 2
- 238000010448 genetic screening Methods 0.000 claims 1
- 230000036039 immunity Effects 0.000 claims 1
- 230000008569 process Effects 0.000 abstract description 7
- 230000009286 beneficial effect Effects 0.000 description 12
- 230000001737 promoting effect Effects 0.000 description 8
- 238000010586 diagram Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 230000009471 action Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000009097 single-agent therapy Methods 0.000 description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 description 2
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 208000028654 hypopharynx squamous cell carcinoma Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
- G16H10/60—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16B20/50—Mutagenesis
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B50/00—ICT programming tools or database systems specially adapted for bioinformatics
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H15/00—ICT specially adapted for medical reports, e.g. generation or transmission thereof
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/70—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
Abstract
The system comprises a database, a server and an intelligent terminal, wherein the database stores patient information summary of different hospital sources (including personal information and diagnosis and treatment information of patients, and the diagnosis and treatment information comprises examination and examination reports, diagnosis and treatment results, treatment schemes, hospital discharge advice and follow-up visit information of the patients). And by accessing the request (containing the unique number of the patient), the database can be inquired to obtain the patient information of the patient, so that corresponding recommendation information is generated and is used for providing assistance for the doctor to diagnose and treat the patient. Therefore, the patient information is conveniently and effectively utilized, and the doctor can consider the patient more comprehensively and perfectly in the diagnosis and treatment process, so that better medical service is provided for the patient.
Description
Technical Field
The application relates to the technical field of medical treatment, in particular to a suggestion generation method and system based on patient information.
Background
In a traditional method for collecting and integrating patient information (personal information, diagnosis and treatment information, postoperative follow-up information and the like), after the patient information is collected from clinic, a doctor or a designated person in a department carries out follow-up registration on telephone, outpatient service and hospitalization information according to project requirements so as to perfect subsequent information. However, the method has the problem of low efficiency, and often, because the patient is a foreign patient, the patient is difficult to collect the information of the patient's visit under the conditions that the patient changes the mobile phone number or performs follow-up visits in different places, the required key information is lost, and the patient has incomplete expression on the relevant required key information.
Further, due to the information barriers between different hospital subjects (for example, hospitals with different names, hospitals at different locations, and the like), it is difficult to share patient information effectively, and therefore, it is difficult to use the information effectively, and it is difficult to improve the level of medical services provided to patients. In the diagnosis and treatment of the patient, a doctor needs to spend a large amount of time to screen and consider the details of the patient, which is not beneficial to improving the working efficiency of the doctor and is also not beneficial to considering the relevant diagnosis and treatment problems more comprehensively and perfectly in the treatment of the patient.
Disclosure of Invention
An object of the embodiments of the present application is to provide a method and a system for generating a recommendation based on patient information, so as to effectively utilize the patient information, and facilitate a doctor to consider more comprehensively and perfectly in a diagnosis and treatment process of a patient, thereby providing a better medical service for the patient.
In order to achieve the above object, embodiments of the present application are implemented as follows:
in a first aspect, an embodiment of the present application provides a patient information-based advice generating method, where a patient information-based advice generating system includes a database, a server, and an intelligent terminal, where the server is in communication with the database and the intelligent terminal, respectively, and the method is applied to the server, and includes: obtaining an access request, wherein the access request comprises a unique number of a patient; inquiring the database for patient information of the patient based on the unique number in the access request, wherein the database stores patient information of different hospital sources, the patient information comprises personal information and diagnosis and treatment information of the patient, and the diagnosis and treatment information comprises at least one of examination and examination reports, diagnosis results, treatment schemes, hospital discharge orders and follow-up information of the patient; generating recommendation information according to the patient information of the patient, wherein the recommendation information is used for providing assistance for a doctor to diagnose and treat the patient.
In the embodiment of the application, the suggestion generation system based on the patient information comprises a database, a server and an intelligent terminal, and the database stores patient information (including personal information and diagnosis and treatment information of patients, and the diagnosis and treatment information includes examination and examination reports, diagnosis results, treatment schemes, hospital discharge orders and follow-up information of the patients) from different hospitals, so that different hospitals can be linked in such a way, and information of the patients after hospitalization in different hospitals can be effectively collected, thereby better providing medical services for the patients. And by accessing the request (containing the unique number of the patient), the database can be inquired to obtain the patient information of the patient, so that corresponding recommendation information is generated and is used for providing assistance for the doctor to diagnose and treat the patient. Therefore, the patient information is conveniently and effectively utilized, and the doctor can consider the patient more comprehensively and perfectly in the diagnosis and treatment process, so that better medical service is provided for the patient.
With reference to the first aspect, in a first possible implementation manner of the first aspect, the patient is an hypopharyngeal carcinoma patient, the diagnosis and treatment information includes a gene detection report, and the generating recommendation information according to the patient information of the patient includes: obtaining immunotherapy gene types in the gene detection report, wherein different immunotherapy gene types are used for reflecting different curative effects of immunotherapy on the patient; and determining the recommendation information according to the immunotherapy gene type, wherein the recommendation information comprises whether the immunotherapy is recommended to the patient.
In this implementation, the patient is a hypopharyngeal squamous carcinoma patient, and the recommendation information (whether immunotherapy is recommended for the patient) is determined according to the immunotherapy gene type by obtaining the immunotherapy gene type in the gene detection report (reflecting the different curative effect that immunotherapy is expected to produce for the patient). In such a way, a treatment scheme suitable for the patient can be recommended to the doctor, the gene detection condition of the patient can be considered, the effect of immunotherapy on the patient can be estimated, and therefore the effect of assisting the doctor in diagnosing and treating the patient can be well achieved.
With reference to the first possible implementation manner of the first aspect, in a second possible implementation manner of the first aspect, the immunotherapy gene types include an immune hyper-progression gene, an immune hypo-efficacy gene, and an immune drug resistance gene, and the obtaining of the immunotherapy gene types in the gene detection report includes: determining mutant gene sites with mutation in preset gene sites according to the gene detection report; and determining the immunotherapy gene type of the mutant gene site according to the mutation type of the mutant gene site.
In the implementation mode, the type of the immunotherapy gene can be accurately and quickly determined by utilizing the mutant gene site with mutation in the preset gene site and combining the mutation type: the gene for the immune super-development, the gene for the poor immune curative effect and the gene for the immune drug resistance are beneficial to providing accurate, reasonable and effective suggestions.
With reference to the second possible implementation manner of the first aspect, in a third possible implementation manner of the first aspect, the predetermined genetic locus includes at least one of CCND1, FGF3, FGF4, FGF19, MDM2, MDM4, and EGFR, the mutation type includes at least one of amplification and harmful mutation, and the determining the immunotherapeutic gene type of the mutant genetic locus according to the mutation type of the mutant genetic locus includes: determining that the immunotherapeutic gene type of the mutant gene site is an immune hyper-progression gene if the mutant gene site comprises any of CCND1, FGF3, FGF4, FGF19, MDM2, MDM4 and the mutation type is an amplification and/or deleterious mutation, or if the mutant gene site is EGFR and the mutation type is amplification; correspondingly, the determining the recommendation information according to the immunotherapy gene type comprises: and determining recommendation information containing a first prompt according to the immune hyper-progression gene, wherein the first prompt is used for prompting a doctor that the patient is not suitable for immunotherapy and recommends using a standard scheme for treatment.
In this implementation, for typing of the immunotherapy gene types, the gene sites such as CCND1, FGF3, FGF4, FGF19, MDM2, MDM4, EGFR, etc., are combined with their specific mutation types (amplification and harmful mutation) to determine whether the immunotherapy gene type of the mutation gene site is an immune hyper-progression gene, thereby determining advice information including a first advice based on the immune hyper-progression gene (the first advice is used to advise a doctor that the patient is not suitable for immunotherapy and recommends treatment using a standard regimen). Therefore, the method can provide reasonable and effective suggestions when the immunotherapy gene type of the patient is the immune hyper-progressive gene, thereby being beneficial to reducing the work of doctors, perfecting the work of the doctors and promoting the medical service level provided for the patient.
With reference to the second possible implementation manner of the first aspect, in a fourth possible implementation manner of the first aspect, the predetermined genetic locus includes at least one of FGFR, NOTCH1, STK11, KEAP1, CCKN2A, CDKN2B, and EGFR, the mutation type includes at least one of amplification, harmful mutation, and deletion mutation, and the determining the immunotherapeutic gene type of the mutant genetic locus according to the mutation type of the mutant genetic locus includes: if the mutant gene locus is FGFR and the mutation type is amplification, determining that the immunotherapy gene type of the mutant gene locus is a gene with poor immunotherapy effect; determining the immunotherapeutic gene type of the mutant gene site as a poorly immunotherapeutic gene if the mutant gene site comprises any one of NOTCH1, STK11, KEAP1, CCKN2A, CDKN2B, EGFR and the mutation type is a deleterious mutation; determining the immunotherapeutic gene type of the mutant genetic locus as a poorly immunotherapeutic gene if the mutant genetic locus comprises any one of CCKN2A and CDKN2B and the mutation type is a deletion mutation; correspondingly, the determining the recommendation information according to the immunotherapy gene type comprises: and determining suggested information containing a second prompt according to the gene with poor immune treatment effect, wherein the second prompt is used for prompting a doctor, and the patient has poor immune treatment effect when using the immune treatment, and recommends an immune combination scheme and close follow-up if using the immune treatment.
In this implementation, for typing of the immunotherapeutic gene types, the gene loci such as FGFR, NOTCH1, STK11, KEAP1, CCKN2A, CDKN2B, EGFR, etc., in combination with their specific mutation types (amplification, detrimental mutation, and deletion mutation), are used to determine whether the immunotherapeutic gene type of the mutant gene locus is a poorly immunotherapeutic gene, thereby determining suggested information including a second prompt based on the poorly immunotherapeutic gene (the second prompt is used to prompt a doctor that the patient is poorly immunotherapeutic, if immunotherapy is needed, an immune combination regimen is recommended and followed closely). Therefore, the method can provide reasonable and effective suggestions when the immunotherapy gene type of the patient is a gene with poor immunotherapy effect, thereby being beneficial to reducing the work of doctors, perfecting the work of the doctors and promoting the medical service level provided for the patient.
With reference to the second possible implementation manner of the first aspect, in a fifth possible implementation manner of the first aspect, the preset genetic locus includes at least one of FGFR, NOTCH1, STK11, KEAP1, CCKN2A, CDKN2B, EGFR, JAK1, and JAK2, the mutation type includes other mutations, and the determining the immunotherapeutic gene type of the mutant genetic locus according to the mutation type of the mutant genetic locus includes: determining the immunotherapeutic gene type of the mutant gene site as a poorly immunotherapeutic gene if the mutant gene site comprises any of FGFR, NOTCH1, STK11, KEAP1, CCKN2A, CDKN2B, EGFR, JAK1, and JAK2 and the mutation type is other mutation; correspondingly, the determining the recommendation information according to the immunotherapy gene type comprises: obtaining detection results of other genes to obtain a PD-L1 CPS score; if the CPS score is larger than or equal to 1, determining suggestion information containing a third prompt, wherein the third prompt is used for prompting a doctor, the patient can select immunotherapy, and when the CPS score is larger than or equal to 20, the patient can be singly treated by using a medicine; if the CPS score is less than 1, determining a recommendation including a fourth prompt for prompting the physician, wherein the patient may be selected for immunotherapy, and an immune combination regimen, preferably an immune combination anti-vascular regimen, is recommended.
In this implementation, for typing of the immunotherapeutic gene types, with the gene loci such as FGFR, NOTCH1, STK11, KEAP1, CCKN2A, CDKN2B, EGFR, JAK1, and JAK2, in combination with specific mutation types thereof (other mutations, i.e., mutation types other than amplification, harmful mutation, deletion mutation, truncation mutation, and the like), it is determined whether the immunotherapeutic gene type of the mutant gene locus is an immunotherapeutic poorly effective gene, so that based on the immunotherapeutic poorly effective gene, further based on the specific size of the PD-L1 score obtained from the detection result of the other genes, the corresponding CPS recommendation information is determined: if the CPS score is greater than or equal to 1, a recommendation is determined that includes a third prompt (for prompting the physician that the patient may be eligible for immunotherapy and that if the CPS score is greater than or equal to 20, the patient may be eligible for monotherapy). If the CPS score is less than 1, a recommendation is determined that includes a fourth prompt (to prompt the physician, the patient may be given an option to immunotherapy, preferably an immune combination regimen or an anti-vascular regimen). Therefore, when the immunotherapy gene type of the patient is a gene with poor immunotherapy effect, the method can provide reasonable and effective suggestions by matching with the PD-L1 CPS score obtained by other gene detection results, thereby being beneficial to reducing the work of doctors, improving the work of doctors and promoting the medical service level provided for the patient.
With reference to the second possible implementation manner of the first aspect, in a sixth possible implementation manner of the first aspect, the determining the immunotherapy gene type of the mutant gene site according to the mutation type of the mutant gene site includes: if the mutant locus comprises any one of JAK1 and JAK2 and the mutation type is deletion mutation, determining the immunotherapy gene type of the mutant locus as an immune drug resistance gene; if the mutant gene locus is EGFR and the mutation type is truncation mutation, determining that the immunotherapy gene type of the mutant gene locus is an immune drug resistance gene; correspondingly, the determining the recommendation information according to the immunotherapy gene type comprises: and determining suggestion information containing a fifth prompt according to the immune drug resistance gene, wherein the fifth prompt is used for prompting a doctor, the patient has poor curative effect and weak evidence grade in immunotherapy, and an immune combination scheme is considered and close follow-up is considered.
In this implementation, for typing of the immunotherapy gene type, the gene sites such as JAK1, JAK2, and EGFR are combined with specific mutation types (deletion mutation and truncation mutation) thereof to determine whether the immunotherapy gene type of the mutation gene site is an immune drug resistance gene, thereby determining advice information including a fifth prompt based on the immune drug resistance gene (the fifth prompt is used to prompt a doctor that the patient has poor curative effect using immunotherapy, and the evidence level is low, and consideration is given to using an immune combination scheme and close follow-up). Therefore, the method can provide reasonable and effective suggestions when the immunotherapy gene type of the patient is the immune drug resistance gene, thereby being beneficial to reducing the work of doctors, perfecting the work of the doctors and promoting the medical service level provided for the patient.
In a second aspect, an embodiment of the present application provides a suggestion generation system based on patient information, including a database, a server and an intelligent terminal, where the server is respectively in communication with the database and the intelligent terminal, the database is used for storing patient information from different hospitals, the patient information includes personal information and diagnosis and treatment information of a patient, and the diagnosis and treatment information includes at least one of a test examination report, a diagnosis result, a treatment plan, a hospital discharge order, and follow-up information of the patient; the intelligent terminal is used for providing an access entrance for a user and generating an access request based on the operation of the user, and comprises at least one of a patient terminal used by a patient, a doctor terminal used by a doctor and a hospital terminal used by a hospital administrator; the server is configured to obtain an access request sent by the intelligent terminal to execute the patient information-based advice generation method according to any one of the first aspect or possible implementation manners of the first aspect.
In order to make the aforementioned objects, features and advantages of the present application more comprehensible, preferred embodiments accompanied with figures are described in detail below.
Drawings
In order to more clearly illustrate the technical solutions of the embodiments of the present application, the drawings that are required to be used in the embodiments of the present application will be briefly described below, it should be understood that the following drawings only illustrate some embodiments of the present application and therefore should not be considered as limiting the scope, and that those skilled in the art can also obtain other related drawings based on the drawings without inventive efforts.
Fig. 1 is a schematic diagram of a recommendation generation system based on patient information according to an embodiment of the present application.
Fig. 2 is a flowchart of a recommendation generation method based on patient information according to an embodiment of the present application.
FIG. 3 is a diagram of the correspondence between the mutated gene loci and the mutation types and the immunotherapy gene types provided in the examples of the present application.
Icon: 100-a recommendation generation system based on patient information; 110-an intelligent terminal; 111-hospital terminals; 112-doctor terminal; 113-a patient terminal; 120-a server; 130-database.
Detailed Description
The technical solutions in the embodiments of the present application will be described below with reference to the drawings in the embodiments of the present application.
Referring to fig. 1, fig. 1 is a schematic diagram of a patient information-based advice generation system 100 according to an embodiment of the present application.
In this embodiment, the patient information based advice generation system 100 may include a database 130, a server 120, and an intelligent terminal 110. The server 120 communicates with the database 130 and the intelligent terminal 110, respectively.
To facilitate an understanding of the patient information based advice generation system 100, a general description of the integration of patient information across hospitals is provided herein.
In the present embodiment, the patient information-based advice generation system 100 may include three-party intelligent terminals 110 (a patient terminal 113 used by a patient, a doctor terminal 112 used by a doctor, and a hospital terminal 111 used by a hospital administrator), and the server 120 may connect different hospital terminals 111, doctor terminals 112, and patient terminals 113. Because the system can assign a unique number to each patient (doctors, hospitals, etc. can also be assigned unique numbers to distinguish different sources of information for the same patient, to distinguish different patients on hand by the same doctor, to distinguish different patients admitted to the same hospital, etc.). The smart terminal 110 may be a smart phone, a tablet computer, a notebook computer, etc., without limitation.
The system adopts the structure, and can collect the information of the same patient through different terminals. For example, the patient is treated in the first hospital at a, and is mainly treated by the S doctor, then the information of the patient may include information such as a test examination report, a diagnosis result, a treatment plan, an order for discharge, and the like, which are entered by the S doctor, and may also include follow-up information, which is additionally entered by the patient through follow-up visits to the patient, and the master that the hospital may store may include the information entered by the doctor, the follow-up information supplemented by the patient, and may also include medication information, consumption information, and the like of the patient in the hospital. It should be noted that each intelligent terminal 110 needs to include a unique number of the patient (a unique number that can be assigned by the patient registration acquisition server 120) when uploading the patient information.
The server 120 may obtain the unique number after receiving the information of any one of the intelligent terminals 110, so as to integrate the information with the same unique number, where of course, the integration process includes processes such as deduplication processing and update processing, and is not described here any more. The server 120 may then store the integrated patient information in the database 130. Of course, the patient terminal 113, the doctor terminal 112, and the hospital terminal 111 can correct and update the information of the patient at any time (only update and correction within their authority).
In addition, it should be noted that the access rights of the patient information-based advice generation system 100 to each type of terminal may be set according to actual needs. For example, in the case of strict protection of patient information, only the individual patient can access his/her own patient information (personal information, medical information, etc.) at any time, and the patient information can be forwarded to or taken to the doctor at the time of visiting the doctor. This protects the patient information from being revealed. The doctor terminal 112 and the hospital terminal 111 can complete the patient information through the doctor terminal 112 or the hospital terminal 111 according to the unique number given by the patient and the authentication information (acquired by the patient terminal 113 or requesting the server 120 to temporarily authorize the corresponding doctor terminal 112 and hospital terminal 111), which is not limited herein.
Illustratively, the database 130 may be used to store patient information from different hospitals, the patient information includes personal information (such as name, age, sex, weight, etc., of course, in order to ensure the differentiation of different patients, each patient corresponds to a unique number) and clinical information (including at least one of examination report, diagnosis result, treatment plan, discharge order, and follow-up information of the patient).
Illustratively, the intelligent terminal 110 may be used to provide an access portal for a user (e.g., a hospital administrator, a doctor, a patient, etc.) and generate an access request based on the user's operation, and the intelligent terminal 110 includes at least one of a patient terminal 113 used by the patient, a doctor terminal 112 used by the doctor, and a hospital terminal 111 used by the hospital administrator.
Illustratively, the server 120 may be configured to obtain an access request sent by the intelligent terminal 110, and execute a recommendation generation method based on the patient information based on the access request.
Referring to fig. 2, fig. 2 is a flowchart of a method for generating a recommendation based on patient information according to an embodiment of the present application. The advice generation method based on the patient information may include step S10, step S20, and step S30.
When a patient is in a visit, the intelligent terminal 110 may generate an access request based on an operation of a user, and the intelligent terminal 110 includes at least one of a patient terminal 113 used by the patient, a doctor terminal 112 used by a doctor, and a hospital terminal 111 used by a hospital administrator. For example, the patient terminal 113 generates an access request and transmits the access request to the server 120 under the operation of the patient, or the doctor terminal 112 generates an access request and transmits the access request to the server 120 under the operation of the doctor. Of course, the access request contains the patient's unique number.
Then the server 120 may perform step S10.
Step S10: an access request is obtained, wherein the access request includes a unique number of a patient.
In this embodiment, the server 120 may receive an access request (including the unique number of the patient) sent by the smart terminal 110.
Then, the server 120 may perform step S20.
Step S20: inquiring the database for patient information of the patient based on the unique number in the access request, wherein the database stores patient information of different hospital sources, the patient information comprises personal information and diagnosis and treatment information of the patient, and the diagnosis and treatment information comprises at least one of examination and examination reports, diagnosis results, treatment schemes, hospital discharge orders and follow-up information of the patient.
In this embodiment, the server 120 may query the database 130 based on the unique number in the access request. For example, the query language may be used to perform a query to obtain all patient information of the patient (including personal information and clinical information of the patient), or the structured query language may be used to query a specific category of information (for example, query clinical information of the patient, without requiring personal information of the patient).
After querying the patient information of the patient, the server 120 may execute step S30.
Step S30: generating recommendation information according to the patient information of the patient, wherein the recommendation information is used for providing assistance for a doctor to diagnose and treat the patient.
In this embodiment, the server 120 may generate advice information according to patient information (mainly, clinical information, or, of course, clinical information and personal information) of the patient.
The suggestion generation system 100 based on patient information comprises a database 130, a server 120 and an intelligent terminal 110, wherein the database 130 stores patient information (including personal information and diagnosis and treatment information of patients, and the diagnosis and treatment information includes examination and examination reports, diagnosis results, treatment schemes, hospital discharge orders and follow-up information of the patients) from different hospitals, so that different hospitals can be connected in such a way, and information of the patients after hospitalization in different hospitals can be effectively collected, thereby better providing medical services for the patients. By accessing the request (including the unique number of the patient), the database 130 can be queried for patient information of the patient, so as to generate corresponding recommendation information for providing assistance to the doctor for diagnosis and treatment of the patient. Therefore, the patient information is conveniently and effectively utilized, and the doctor can consider the patient more comprehensively and perfectly in the diagnosis and treatment process, so that better medical service is provided for the patient.
For example, when the patient is a hypopharyngeal squamous cell carcinoma patient and the diagnosis and treatment information includes a gene testing report, the server 120 may obtain the immunotherapy gene types in the gene testing report, wherein different immunotherapy gene types are used for reflecting different curative effects expected to be produced on the patient by the immunotherapy. The server 120 can then determine recommendation information based on the immunotherapy gene type, wherein the recommendation information includes whether immunotherapy is recommended for the patient.
The patient is the hypopharyngeal squamous carcinoma patient, the immunotherapy gene type in the gene detection report is obtained (reflecting different curative effects of immunotherapy on the patient is expected), and then recommendation information (whether immunotherapy is recommended to the patient) is determined according to the immunotherapy gene type. In such a way, a treatment scheme suitable for the patient can be recommended to the doctor, the gene detection condition of the patient can be considered, the effect of immunotherapy on the patient can be estimated, and therefore the effect of assisting the doctor in diagnosing and treating the patient can be well achieved.
Specifically, the immunotherapy gene types may include an immune hyper-progression gene, an immune poor-treatment gene, and an immune drug resistance gene, and then the server 120 may determine, according to the gene detection report, a mutated gene site having a mutation in the preset gene sites (which may be understood as a marked gene site, and mainly check whether the gene sites have a mutation); then, according to the mutation type of the mutation gene site, the immunotherapy gene type of the mutation gene site is determined.
The method can accurately and quickly determine the types of the immunotherapy genes by utilizing the mutant gene sites with mutation in the preset gene sites and combining the mutation types: the gene for the immune super-development, the gene for the poor immune curative effect and the gene for the immune drug resistance are beneficial to providing accurate, reasonable and effective suggestions.
Referring to fig. 3, fig. 3 is a diagram of the correspondence between the mutation loci and the mutation types and the immunotherapy gene types provided in the embodiment of the present application.
Therefore, the server 120 can determine the different situations in the following manners:
first, when the predetermined gene site includes at least one of CCND1, FGF3, FGF4, FGF19, MDM2, MDM4, and EGFR, and the mutation type includes at least one of amplification and harmful mutation, the server 120 determines the immunotherapeutic gene type of the mutation gene site by:
the server 120 may determine whether CCND1, FGF3, FGF4, FGF19, MDM2, MDM4, EGFR contain a genetic locus that generates a mutation, and the type of mutation at the mutated genetic locus.
If the mutated genetic locus comprises any one of CCND1, FGF3, FGF4, FGF19, MDM2, MDM4, and the mutation type is an amplification and/or deleterious mutation, server 120 can determine the immunotherapeutic gene type of the mutated genetic locus as an immune hyper-progression gene. And when the mutation gene site is EGFR and the mutation type is amplification, the server 120 may also determine that the immunotherapy gene type of the mutation gene site is an immune hyper-progression gene.
Accordingly, the server 120 can determine a recommendation message including a first prompt for prompting the doctor that the patient is not suitable for immunotherapy and recommends treatment using a standard protocol based on the immune hyper-progression gene.
The gene sites of CCND1, FGF3, FGF4, FGF19, MDM2, MDM4, EGFR and the like are combined with specific mutation types (amplification and harmful mutation) to judge whether the immunotherapy gene type of the mutation gene site is an immune hyper-progression gene, so that advice information containing a first prompt is determined based on the immune hyper-progression gene (the first prompt is used for prompting a doctor, and the patient is not suitable for immunotherapy and recommends to be treated by a standard scheme). Therefore, the method can provide reasonable and effective suggestions when the immunotherapy gene type of the patient is the immune hyper-progressive gene, thereby being beneficial to reducing the work of doctors, perfecting the work of the doctors and promoting the medical service level provided for the patient.
Secondly, when the predetermined genetic locus includes at least one of FGFR, NOTCH1, STK11, KEAP1, CCKN2A, CDKN2B, and EGFR, and the mutation type includes at least one of amplification, harmful mutation, and deletion mutation, the manner of determining the immunotherapeutic gene type of the mutated genetic locus by the server 120 may be:
the server 120 can determine whether the FGFR, NOTCH1, STK11, KEAP1, CCKN2A, CDKN2B, EGFR contain the gene locus where the mutation is generated, and the mutation type of the mutation gene locus.
If the mutated genomic locus is FGFR and the mutation type is amplification, the server 120 may determine that the immunotherapeutic genomic type of the mutated genomic locus is a poorly immunotherapeutic gene.
If the mutant gene site comprises any one of NOTCH1, STK11, KEAP1, CCKN2A, CDKN2B and EGFR, and the mutation type is a harmful mutation, the server 120 can determine that the immunotherapeutic gene type of the mutant gene site is a poor immunotherapeutic gene.
If the mutant gene locus comprises any one of CCKN2A and CDKN2B and the mutation type is a deletion mutation, the server 120 can determine that the immunotherapeutic gene type of the mutant gene locus is an immunotherapeutic poorly efficient gene.
Correspondingly, the server 120 may determine suggested information including a second prompt according to the poor-immune-treatment gene, wherein the second prompt is used for prompting the doctor that the patient has poor-immune-treatment effect, and if the patient needs to use the immune-treatment, the patient recommends an immune combination scheme and follows up closely.
And (3) determining suggestion information containing a second prompt based on the genes with poor immune curative effect by judging whether the types of the immunotherapy genes of the mutant gene sites are genes with poor immune curative effect by using the gene sites such as FGFR, NOTCH1, STK11, KEAP1, CCKN2A, CDKN2B, EGFR and the like and combining specific mutation types (amplification, harmful mutation and deletion mutation) of the gene sites, thereby determining the suggestion information based on the genes with poor immune curative effect (the second prompt is used for prompting a doctor that the patient uses the poor immune curative effect, if the patient needs to use the immune curative, an immune combination scheme is recommended and closely follows the doctor). Therefore, the method can provide reasonable and effective suggestions when the immunotherapy gene type of the patient is a gene with poor immunotherapy effect, thereby being beneficial to reducing the work of doctors, perfecting the work of the doctors and promoting the medical service level provided for the patient.
Thirdly, when the preset gene locus includes at least one of FGFR, NOTCH1, STK11, KEAP1, CCKN2A, CDKN2B, EGFR, JAK1, and JAK2 and the mutation type is other mutations, the mode of the server 120 for determining the immunotherapy gene type of the mutation gene locus may be:
the server 120 can determine whether the FGFR, NOTCH1, STK11, KEAP1, CCKN2A, CDKN2B, EGFR, JAK1, and JAK2 include a mutation-producing genetic locus, and a mutation type of the mutated genetic locus.
If the mutant gene site comprises any one of FGFR, NOTCH1, STK11, KEAP1, CCKN2A, CDKN2B, EGFR, JAK1, and JAK2, and the mutation type is other mutation, the server 120 may determine that the immunotherapeutic gene type of the mutant gene site is a poorly immunotherapeutic gene.
Accordingly, the server 120 may obtain other gene detection results, resulting in a PD-L1 CPS score.
If the CPS score is greater than or equal to 1, the server 120 may determine a recommendation including a third prompt for the physician, wherein the patient may be selected for immunotherapy and may be treated with a single medication if the CPS score is greater than or equal to 20.
If the CPS score is less than 1, the server 120 may determine a recommendation including a fourth prompt prompting the physician that the patient may be treated with an alternative immunotherapy suggesting an immune combination regimen, preferably an immune combination anti-vascular regimen.
By using gene loci such as FGFR, NOTCH1, STK11, KEAP1, CCKN2A, CDKN2B, EGFR, JAK1 and JAK2 and combining specific mutation types (other mutations, namely mutation types except amplification, harmful mutation, deletion mutation, truncation mutation and the like), judging whether the immunotherapy gene type of the mutation gene locus is a gene with poor immune curative effect or not, and determining corresponding suggested information based on the gene with poor immune curative effect and further based on the specific size of a PD-L1 CPS score obtained by the detection result of other genes: if the CPS score is greater than or equal to 1, a recommendation is determined that includes a third prompt (for prompting the physician that the patient may be eligible for immunotherapy and that if the CPS score is greater than or equal to 20, the patient may be eligible for monotherapy). If the CPS score is less than 1, a recommendation is determined that includes a fourth prompt (to prompt the physician, the patient may be given an option to immunotherapy, preferably an immune combination regimen or an anti-vascular regimen). Therefore, when the immunotherapy gene type of the patient is a gene with poor immunotherapy effect, the method can provide reasonable and effective suggestions by matching with the PD-L1 CPS score obtained by other gene detection results, thereby being beneficial to reducing the work of doctors, improving the work of doctors and promoting the medical service level provided for the patient.
Fourthly, when the preset gene locus comprises at least one of JAK1, JAK2 and EGFR, and the mutation type comprises at least one of deletion mutation and truncation mutation, the mode of determining the immunotherapy gene type of the mutation gene locus by the server 120 may be:
the server 120 can determine whether JAK1, JAK2, and EGFR include a genetic locus where a mutation occurs, and the type of mutation at the genetic locus.
If the mutant gene site includes any one of JAK1 and JAK2, and the mutation type is a deletion mutation, the server 120 may determine that the immunotherapeutic gene type of the mutant gene site is an immune drug resistance gene.
If the mutated genetic locus is EGFR and the mutation type is a truncation mutation, the server 120 may determine that the immunotherapeutic gene type of the mutated genetic locus is an immune drug resistance gene.
Correspondingly, the server 120 may determine recommendation information including a fifth prompt according to the immune resistance gene, wherein the fifth prompt is used for prompting a doctor that the patient has poor curative effect and weak evidence level in the immunotherapy, and considers using an immune combination scheme and close follow-up.
And (3) judging whether the immunotherapy gene type of the mutant gene site is an immune drug resistance gene or not by combining the specific mutation types (deletion mutation and truncation mutation) of the JAK1, JAK2, EGFR and other gene sites, and determining suggestion information containing a fifth prompt based on the immune drug resistance gene (the fifth prompt is used for prompting a doctor that the patient has poor curative effect when using immunotherapy and has a weak evidence level, and the patient is considered to use an immune combination scheme and closely follow up). Therefore, the method can provide reasonable and effective suggestions when the immunotherapy gene type of the patient is the immune drug resistance gene, thereby being beneficial to reducing the work of doctors, perfecting the work of the doctors and promoting the medical service level provided for the patient.
In summary, the present application provides a method and a system for generating a recommendation based on patient information, where the system 100 for generating a recommendation based on patient information includes a database 130, a server 120, and an intelligent terminal 110, and the database 130 stores patient information (including personal information and medical information of a patient, and the medical information includes examination and examination reports, diagnosis results, treatment plans, discharge orders, and follow-up information of the patient) from different hospitals, so that in this way, different hospitals can be linked, and information after the patient visits at different hospitals can be effectively collected, thereby better providing medical services for the patient. By accessing the request (including the unique number of the patient), the database 130 can be queried for patient information of the patient, so as to generate corresponding recommendation information for providing assistance to the doctor for diagnosis and treatment of the patient. Therefore, the patient information is conveniently and effectively utilized, and the doctor can consider the patient more comprehensively and perfectly in the diagnosis and treatment process, so that better medical service is provided for the patient.
In this document, relational terms such as first and second, and the like may be used solely to distinguish one entity or action from another entity or action without necessarily requiring or implying any actual such relationship or order between such entities or actions.
The above description is only an example of the present application and is not intended to limit the scope of the present application, and various modifications and changes may be made by those skilled in the art. Any modification, equivalent replacement, improvement and the like made within the spirit and principle of the present application shall be included in the protection scope of the present application.
Claims (8)
1. A patient information-based advice generating method is characterized in that a patient information-based advice generating system comprises a database, a server and an intelligent terminal, wherein the server is respectively communicated with the database and the intelligent terminal, and the method is applied to the server and comprises the following steps:
obtaining an access request, wherein the access request comprises a unique number of a patient;
inquiring the database for patient information of the patient based on the unique number in the access request, wherein the database stores patient information of different hospital sources, the patient information comprises personal information and diagnosis and treatment information of the patient, and the diagnosis and treatment information comprises at least one of examination and examination reports, diagnosis results, treatment schemes, hospital discharge orders and follow-up information of the patient;
generating recommendation information according to the patient information of the patient, wherein the recommendation information is used for providing assistance for a doctor to diagnose and treat the patient.
2. The method of claim 1, wherein the patient is an hypopharyngeal carcinoma patient, the medical information includes a genetic screening report, and the generating of the advice information based on the patient information of the patient includes:
obtaining immunotherapy gene types in the gene detection report, wherein different immunotherapy gene types are used for reflecting different curative effects of immunotherapy on the patient;
and determining the recommendation information according to the immunotherapy gene type, wherein the recommendation information comprises whether the immunotherapy is recommended to the patient.
3. The method of claim 2, wherein the immunotherapy gene types include hyper-progression of immunity gene, hypo-immunotherapy gene, and immuno-drug resistance gene, and the obtaining of the immunotherapy gene types in the gene detection report comprises:
determining mutant gene sites with mutation in preset gene sites according to the gene detection report;
and determining the immunotherapy gene type of the mutant gene site according to the mutation type of the mutant gene site.
4. The patient information-based advice generation method of claim 3, wherein the predetermined genetic locus comprises at least one of CCND1, FGF3, FGF4, FGF19, MDM2, MDM4, and EGFR, wherein the mutation type comprises at least one of an amplification mutation and a deleterious mutation, and wherein determining the immunotherapeutic gene type for the mutation genetic locus based on the mutation type of the mutation genetic locus comprises:
determining that the immunotherapeutic gene type of the mutant gene site is an immune hyper-progression gene if the mutant gene site comprises any of CCND1, FGF3, FGF4, FGF19, MDM2, MDM4 and the mutation type is an amplification and/or deleterious mutation, or if the mutant gene site is EGFR and the mutation type is amplification;
correspondingly, the determining the recommendation information according to the immunotherapy gene type comprises:
and determining recommendation information containing a first prompt according to the immune hyper-progression gene, wherein the first prompt is used for prompting a doctor that the patient is not suitable for immunotherapy and recommends using a standard scheme for treatment.
5. The patient information-based advice generation method of claim 3, wherein the predetermined loci include at least one of FGFR, NOTCH1, STK11, KEAP1, CCKN2A, CDKN2B and EGFR, the mutation types include at least one of amplification, deleterious mutation and deletion mutation, and the determining the immunotherapeutic gene type of the mutant loci according to the mutation types of the mutant loci comprises:
if the mutant gene locus is FGFR and the mutation type is amplification, determining that the immunotherapy gene type of the mutant gene locus is a gene with poor immunotherapy effect;
determining the immunotherapeutic gene type of the mutant gene site as a poorly immunotherapeutic gene if the mutant gene site comprises any one of NOTCH1, STK11, KEAP1, CCKN2A, CDKN2B, EGFR and the mutation type is a deleterious mutation;
determining the immunotherapeutic gene type of the mutant genetic locus as a poorly immunotherapeutic gene if the mutant genetic locus comprises any one of CCKN2A and CDKN2B and the mutation type is a deletion mutation;
correspondingly, the determining the recommendation information according to the immunotherapy gene type comprises:
and determining suggested information containing a second prompt according to the gene with poor immune treatment effect, wherein the second prompt is used for prompting a doctor, and the patient has poor immune treatment effect when using the immune treatment, and recommends an immune combination scheme and close follow-up if using the immune treatment.
6. The patient information-based advice generation method of claim 3, wherein the predetermined loci include at least one of FGFR, NOTCH1, STK11, KEAP1, CCKN2A, CDKN2B, EGFR, JAK1, and JAK2, and wherein the mutation types include other mutations, and wherein determining the immunotherapeutic gene type of the mutated loci from the mutation types of the mutated loci comprises:
determining the immunotherapeutic gene type of the mutant gene site as a poorly immunotherapeutic gene if the mutant gene site comprises any of FGFR, NOTCH1, STK11, KEAP1, CCKN2A, CDKN2B, EGFR, JAK1, and JAK2 and the mutation type is other mutation;
correspondingly, the determining the recommendation information according to the immunotherapy gene type comprises:
obtaining detection results of other genes to obtain a PD-L1 CPS score;
if the CPS score is larger than or equal to 1, determining suggestion information containing a third prompt, wherein the third prompt is used for prompting a doctor, the patient can select immunotherapy, and when the CPS score is larger than or equal to 20, the patient can be singly treated by using a medicine;
if the CPS score is less than 1, determining a recommendation including a fourth prompt for prompting the physician, wherein the patient may be selected for immunotherapy, and an immune combination regimen, preferably an immune combination anti-vascular regimen, is recommended.
7. The patient information-based advice generation method of claim 3, wherein the predetermined loci include at least one of JAK1, JAK2 and EGFR, the mutation types include at least one of deletion mutation and truncation mutation, and the determining the immunotherapeutic gene type of the mutated locus according to the mutation type of the mutated locus includes:
if the mutant locus comprises any one of JAK1 and JAK2 and the mutation type is deletion mutation, determining the immunotherapy gene type of the mutant locus as an immune drug resistance gene;
if the mutant gene locus is EGFR and the mutation type is truncation mutation, determining that the immunotherapy gene type of the mutant gene locus is an immune drug resistance gene;
correspondingly, the determining the recommendation information according to the immunotherapy gene type comprises:
and determining suggestion information containing a fifth prompt according to the immune drug resistance gene, wherein the fifth prompt is used for prompting a doctor, the patient has poor curative effect and weak evidence grade in immunotherapy, and an immune combination scheme is considered and close follow-up is considered.
8. A patient information-based advice generation system, comprising a database, a server and an intelligent terminal, the server being in communication with the database and the intelligent terminal, respectively,
the database is used for storing patient information from different hospital sources, the patient information comprises personal information and diagnosis and treatment information of patients, and the diagnosis and treatment information comprises at least one of examination and examination reports, diagnosis results, treatment schemes, hospital discharge advice and follow-up information of the patients;
the intelligent terminal is used for providing an access entrance for a user and generating an access request based on the operation of the user, and comprises at least one of a patient terminal used by a patient, a doctor terminal used by a doctor and a hospital terminal used by a hospital administrator;
the server is used for acquiring the access request sent by the intelligent terminal so as to execute the patient information-based suggestion generation method of any one of claims 1 to 7.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110746320.1A CN113345543A (en) | 2021-07-01 | 2021-07-01 | Suggestion generation method and system based on patient information |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110746320.1A CN113345543A (en) | 2021-07-01 | 2021-07-01 | Suggestion generation method and system based on patient information |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113345543A true CN113345543A (en) | 2021-09-03 |
Family
ID=77482099
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110746320.1A Pending CN113345543A (en) | 2021-07-01 | 2021-07-01 | Suggestion generation method and system based on patient information |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113345543A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106650256A (en) * | 2016-12-20 | 2017-05-10 | 安徽安龙基因医学检验所有限公司 | Precise medical platform for molecular diagnosis and treatment |
| CN112143810A (en) * | 2020-09-29 | 2020-12-29 | 南方医科大学中西医结合医院 | Gene markers for predicting cancer immunotherapy effect and application thereof |
| CN112667584A (en) * | 2020-12-23 | 2021-04-16 | 复旦大学附属儿科医院 | Patient information storage sharing system |
-
2021
- 2021-07-01 CN CN202110746320.1A patent/CN113345543A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106650256A (en) * | 2016-12-20 | 2017-05-10 | 安徽安龙基因医学检验所有限公司 | Precise medical platform for molecular diagnosis and treatment |
| CN112143810A (en) * | 2020-09-29 | 2020-12-29 | 南方医科大学中西医结合医院 | Gene markers for predicting cancer immunotherapy effect and application thereof |
| CN112667584A (en) * | 2020-12-23 | 2021-04-16 | 复旦大学附属儿科医院 | Patient information storage sharing system |
Non-Patent Citations (2)
| Title |
|---|
| 佚名: "免疫治疗有效率78.8%和0%的患者只有一个区别", 《搜狐》 * |
| 汤凌浩等: "喉鳞癌染色体核型的检测和分析", 《吉林医药学院学报》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN112700838B (en) | Big data-based medication scheme recommendation method and device and related equipment | |
| AU2007202746B2 (en) | Systems and methods for refining identification of clinical study candidates | |
| US7599846B2 (en) | Method for renewing medical prescriptions | |
| US20080010254A1 (en) | Systems and methods for enrollment of clinical study candidates and investigators | |
| US20110046975A1 (en) | Dynamically adjusted rules-based decision support using site-specific mapped values | |
| US8781849B1 (en) | System for and method of enhancing patient's healthcare by utilizing provider-generated data | |
| US8346575B2 (en) | System and methods of automated patient check-in, scheduling and prepayment | |
| US9268906B2 (en) | Methods, apparatuses and computer program products for facilitating location and retrieval of health information in a healthcare system | |
| CN109166622B (en) | Disease pre-diagnosis system based on knowledge graph | |
| WO2013036853A2 (en) | Medical information systems and medical data processing methods | |
| JP2023018074A (en) | Disease diagnosis/medical treatment/prevention system | |
| US20090204439A1 (en) | Apparatus and method for managing electronic medical records embedded with decision support tools | |
| JP2009266077A (en) | Electronic medical chart management server and electronic medical chart management system | |
| Selby et al. | Differences in resource use and costs of primary care in a large HMO according to physician specialty. | |
| Yu et al. | Willingness, preferred ways and potential barriers to use pre-exposure prophylaxis for HIV prevention among men who have sex with men in China | |
| Harney et al. | A multi‐site, nurse‐coordinated hepatitis C model of care in primary care and community services in Melbourne, Australia | |
| WO2016040359A1 (en) | Structuring multi-sourced medical information into a collaborative health record | |
| CN113345543A (en) | Suggestion generation method and system based on patient information | |
| US20070038037A1 (en) | Method and apparatus for symptom-based order protocoling within the exam ordering process | |
| Le et al. | Experience with a managed care approach to HIV infection: effectiveness of an interdisciplinary team | |
| JP2009266076A (en) | Electronic medical chart management server and electronic medical chart management system | |
| US11481731B2 (en) | Identifying ownership of a healthcare clinic based on enrollment information | |
| Alegría et al. | Performance metrics of substance use disorder care among Medicaid enrollees in New York, New York | |
| JPH11306261A (en) | Patient information sharing system | |
| US20070260478A1 (en) | Delivery of Health Insurance Plan Options |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210903 |